Johnson & Johnson MedTech President of U.S. Orthopaedics Leslie Storms. [Image from LinkedIn]Johnson & Johnson MedTech
(NYSE: JNJ)
+
President of U.S. Orthopaedics Leslie Storms announced that she is leaving the company this month.
On LinkedIn, Storms posted that she is departing the medtech giant after 18 years.
“I’ve had the great fortune to work with amazing leaders and talented teams filled with people passionate about ‘what’ they do because they are passionate about ‘who’ they ultimately serve—patients,” Storms wrote. “I’ve had the great fortune to work for a company that has helped me grow, challenged me to think differently, urged me to bring expertise but also fresh eyes, and supported me and my family at every turn.”
This departure comes as J&J looks to separate its DePuy Synthes Orthopaedics business, announcing the decision last month. The company said the separation aims to enhance the strategic and operational focus of each company while driving stakeholder value. (Tim Schmid, J&J MedTech’s EVP and worldwide chair, spoke about this decision at DeviceTalks West last month.)
According to LinkedIn, Storms began her career at J&J as VP of global sales & marketing at its Noramco active pharmaceutical ingredients (API) manufacturing unit, which it eventually sold in 2016. In 2013, she became a senior marketing director for CNS within the company’s Janssen unit.
Storms moved to J&J Vision, holding multiple VP roles there for three years before switching to the company’s MedTech unit. She became VP of sales for Surgery, then president of sales for Surgery, before taking over as president of Orthopaedics in 2023.
“I leave J&J with tremendous gratitude and ‘prepped’ for my next chapter,” Storms wrote. “Wishing you all the best and we’ll chat again soon.”